CD22 and neoplasm: Additionally, 211At-labeled anti-CD22 RIT has emerged as a promising alternative for B-cell malignancies, benefiting from the short-range, high-energy α-particle emissions, which enhance tumor cell killing while minimizing off-target toxicity [66].